Cargando…

A Tetravalent Biparatopic Antibody Causes Strong HER2 Internalization and Inhibits Cellular Proliferation

The overexpression of tyrosine kinase HER2 in numerous cancers, connected with fierce signaling and uncontrolled proliferation, makes it a suitable target for immunotherapy. The acquisition of resistance to currently used compounds and the multiplicity of signaling pathways involved prompted researc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Benedetti, Filippo, Stadlbauer, Katharina, Stadlmayr, Gerhard, Rüker, Florian, Wozniak-Knopp, Gordana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8624325/ https://www.ncbi.nlm.nih.gov/pubmed/34833033 http://dx.doi.org/10.3390/life11111157

Ejemplares similares

Bispecific antibodies with Fab-arms featuring exchanged antigen-binding constant domains
por: Benedetti, Filippo, et al.
Publicado: (2021)

Bispecific mAb(2) Antibodies Targeting CD59 Enhance the Complement-Dependent Cytotoxicity Mediated by Rituximab
por: Stadlbauer, Katharina, et al.
Publicado: (2022)

An antibody with Fab-constant domains exchanged for a pair of C(H)3 domains
por: Wozniak-Knopp, Gordana, et al.
Publicado: (2018)

An engineered CD81‐based combinatorial library for selecting recombinant binders to cell surface proteins: Laminin binding CD81 enhances cellular uptake of extracellular vesicles
por: Vogt, Stefan, et al.
Publicado: (2021)

Stabilization of soluble high‐affinity T‐cell receptor with de novo disulfide bonds
por: Sádio, Flávio, et al.
Publicado: (2019)

Bispecific T-Cell Engagers Targeting Membrane-Bound IgE
por: Rodak, Aleksandra, et al.
Publicado: (2021)

Stabilization of the CD81 Large Extracellular Loop with De Novo Disulfide Bonds Improves Its Amenability for Peptide Grafting
por: Vogt, Stefan, et al.
Publicado: (2018)

Development of a Cytotoxic Antibody–Drug Conjugate Targeting Membrane Immunoglobulin E-Positive Cells
por: Rodak, Aleksandra, et al.
Publicado: (2023)

Stability assessment on a library scale: a rapid method for the evaluation of the commutability and insertion of residues in C-terminal loops of the CH3 domains of IgG1-Fc
por: Hasenhindl, Christoph, et al.
Publicado: (2013)

Engineering an anti-HER2 biparatopic antibody with a multimodal mechanism of action
por: Kast, Florian, et al.
Publicado: (2021)

Stabilisation of the Fc Fragment of Human IgG1 by Engineered Intradomain Disulfide Bonds
por: Wozniak-Knopp, Gordana, et al.
Publicado: (2012)

Structural insights into the mechanism of action of a biparatopic anti-HER2 antibody
por: Oganesyan, Vaheh, et al.
Publicado: (2018)

Binding Characteristic of Various Antibody Formats Against Aflatoxins
por: Rangnoi, Kuntalee, et al.
Publicado: (2021)

An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity
por: Weisser, Nina E., et al.
Publicado: (2023)

Molecular Mechanism of HER2 Rapid Internalization and Redirected Trafficking Induced by Anti-HER2 Biparatopic Antibody
por: Cheng, Jackie, et al.
Publicado: (2020)

Construction of pH-sensitive Her2-binding IgG1-Fc by directed evolution
por: Traxlmayr, Michael W, et al.
Publicado: (2014)

Directed evolution of stabilized IgG1-Fc scaffolds by application of strong heat shock to libraries displayed on yeast
por: Traxlmayr, Michael W., et al.
Publicado: (2012)

JSKN003, A NOVEL BIPARATOPIC ANTI-HER2 ANTIBODY-DRUG CONJUGATE, EXHIBITS POTENT ANTITUMOR EFFICACY
por: Wang, Pilin, et al.
Publicado: (2023)

Designed SARS‐CoV‐2 receptor binding domain variants form stable monomers
por: Klausberger, Miriam, et al.
Publicado: (2022)

Bp-Bs, a Novel T-cell Engaging Bispecific Antibody with Biparatopic Her2 Binding, Has Potent Anti-tumor Activities
por: Liu, Jiayu, et al.
Publicado: (2019)

A biparatopic agonistic antibody that mimics fibroblast growth factor 21 ligand activity
por: Shi, Sally Yu, et al.
Publicado: (2018)

First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody–Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer
por: Pegram, Mark D., et al.
Publicado: (2021)

Enhancement of Polymeric Immunoglobulin Receptor Transcytosis by Biparatopic VHH
por: Emmerson, Chris D., et al.
Publicado: (2011)

Biparatopic Protein Nanoparticles for the Precision Therapy of CXCR4(+) Cancers
por: Cano-Garrido, Olivia, et al.
Publicado: (2021)

Generation of biparatopic antibody through two-step targeting of fragment antibodies on antigen using SpyTag and SpyCatcher
por: Akiba, Hiroki, et al.
Publicado: (2020)

Targeted Fcγ Receptor (FcγR)-mediated Clearance by a Biparatopic Bispecific Antibody
por: Kasturirangan, Srinath, et al.
Publicado: (2017)

Expeditious Generation of Biparatopic Common Light Chain Antibodies via Chicken Immunization and Yeast Display Screening
por: Bogen, Jan P., et al.
Publicado: (2020)

CD38-Specific Biparatopic Heavy Chain Antibodies Display Potent Complement-Dependent Cytotoxicity Against Multiple Myeloma Cells
por: Schütze, Kerstin, et al.
Publicado: (2018)

Multiplex LC-MS/MS Assays for Clinical Bioanalysis of MEDI4276, an Antibody-Drug Conjugate of Tubulysin Analogue Attached via Cleavable Linker to a Biparatopic Humanized Antibody against HER-2
por: Faria, Morse, et al.
Publicado: (2019)

TNB-738, a biparatopic antibody, boosts intracellular NAD+ by inhibiting CD38 ecto-enzyme activity
por: Ugamraj, Harshad S., et al.
Publicado: (2022)

A tetravalent dengue nanoparticle stimulates antibody production in mice
por: Silva, Elisângela F, et al.
Publicado: (2012)

Creating stable stem regions for loop elongation in Fcabs — Insights from combining yeast surface display, in silico loop reconstruction and molecular dynamics simulations
por: Hasenhindl, Christoph, et al.
Publicado: (2014)

Construction of a Stability Landscape of the CH3 Domain of Human IgG1 by Combining Directed Evolution with High Throughput Sequencing
por: Traxlmayr, Michael W., et al.
Publicado: (2012)

A highly potent CD73 biparatopic antibody blocks organization of the enzyme active site through dual mechanisms
por: Stefano, James E., et al.
Publicado: (2021)

A Biparatopic Antibody–Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade
por: DaSilva, John O., et al.
Publicado: (2021)

Dual anti-idiotypic purification of a novel, native-format biparatopic anti-MET antibody with improved in vitro and in vivo efficacy
por: Godar, Marie, et al.
Publicado: (2016)

A novel biparatopic hybrid antibody-ACE2 fusion that blocks SARS-CoV-2 infection: implications for therapy
por: Miao, Xiaoniu, et al.
Publicado: (2020)

An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants
por: Chi, Xiaojing, et al.
Publicado: (2022)

Biparatopic sybodies neutralize SARS‐CoV‐2 variants of concern and mitigate drug resistance
por: Walter, Justin D, et al.
Publicado: (2022)

Biparatopic nanobodies targeting the receptor binding domain efficiently neutralize SARS-CoV-2
por: Pymm, Phillip, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_j28qqhtllvrmhs8hjiuv7q20sh